Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3',5'-cyclic-amp phosphodiesterase deficiency
Cardiac Overexpression of PDE4B Blunts ?-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
3',5'-cyclic-amp phosphodiesterase deficiency
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
3',5'-cyclic-amp phosphodiesterase deficiency
Reduced adiposity and high fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.
3',5'-cyclic-amp phosphodiesterase deficiency
Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice.
Acquired Immunodeficiency Syndrome
Novel GFP-fused protein probes for detecting phosphatidylinositol-4-phosphate in the plasma membrane.
Acute Kidney Injury
Rutaecarpine derivative Cpd-6c alleviates acute kidney injury by targeting PDE4B, a key enzyme mediating inflammation in cisplatin nephropathy.
Acute Lung Injury
Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.
Acute Lung Injury
Additive effects of phosphodiesterase-4 inhibition on effects of rSP-C surfactant.
Acute Lung Injury
Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.
Acute Lung Injury
Effects of roflumilast, a phosphodiesterase-4 inhibitor, on the lung functions in a saline lavage-induced model of acute lung injury.
Acute Lung Injury
Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: An animal study.
Acute Lung Injury
Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
Acute Lung Injury
Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Acute Lung Injury
The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between Tumor necrosis factor-alpha and interleukin-10.
Acute Lung Injury
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury.
Adenocarcinoma, Follicular
Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.
Adenoma
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Adenoma
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Adenoma
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Adenoma
The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.
Airway Obstruction
In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood.
Alcoholic Neuropathy
Electrophysiological and behavioral changes by phosphodiesterase 4 inhibitor in a rat model of alcoholic neuropathy.
Alopecia Areata
Development of alopecia areata during phosphodiesterase 4 inhibitor treatment for psoriasis: A case report.
Alopecia Areata
Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
Alzheimer Disease
A Hypothesis and Evidence That Mercury May be an Etiological Factor in Alzheimer's Disease.
Alzheimer Disease
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
Alzheimer Disease
Etazolate improves performance in a foraging and homing task in aged rats.
Alzheimer Disease
FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
Alzheimer Disease
Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
Alzheimer Disease
Increased isoform-specific phosphodiesterase 4D expression is associated with pathology and cognitive impairment in Alzheimer's disease.
Alzheimer Disease
Inverse Molecular Docking as a Novel Approach to Study Anticarcinogenic and Anti-Neuroinflammatory Effects of Curcumin.
Alzheimer Disease
Phosphodiesterase 4D Gene Modifies the Functional Network of Patients With Mild Cognitive Impairment and Alzheimer's Disease.
Alzheimer Disease
Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease.
Alzheimer Disease
Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
Alzheimer Disease
Phosphodiesterase-4D Knockdown in the Prefrontal Cortex Alleviates Memory Deficits and Synaptic Failure in Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Alzheimer Disease
The phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer's disease: a preclinical study in APP/PS1 transgenic mice.
Amnesia
Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents.
Amnesia
Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats.
Anaphylaxis
An isoenzyme-selective inhibitor of phosphodiesterase 4 and 1, KF19514, may be useful in the treatment of systemic anaphylaxis: an in vivo study in rabbits.
Anhedonia
Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.
Aortic Aneurysm, Abdominal
Rolipram Prevents the Formation of Abdominal Aortic Aneurysm (AAA) in Mice: PDE4B as a Target in AAA.
Apnea
Reversal by phosphodiesterase-4 blockers of in vitro apnea in the isolated brainstem-spinal cord preparation from newborn rats.
Arrhythmias, Cardiac
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arthritis
Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.
Arthritis
Ciclamilast ameliorates adjuvant-induced arthritis in a rat model.
Arthritis
Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.
Arthritis
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Arthritis
Psoriatic Arthritis: Newer and Older Therapies.
Arthritis
The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
Arthritis, Experimental
Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
Arthritis, Juvenile
The autonomic nervous system and the immune system in juvenile rheumatoid arthritis.
Arthritis, Psoriatic
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Arthritis, Psoriatic
Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B.
Arthritis, Psoriatic
Apremilast for psoriasis treatment.
Arthritis, Psoriatic
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Arthritis, Psoriatic
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
Arthritis, Psoriatic
Apremilast in Refractory Alopecia Areata.
Arthritis, Psoriatic
Apremilast in the Management of Disseminated Granuloma Annulare.
Arthritis, Psoriatic
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
Arthritis, Psoriatic
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Arthritis, Psoriatic
Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.
Arthritis, Psoriatic
Apremilast monotherapy for palmoplantar pustulosis: Report of three cases.
Arthritis, Psoriatic
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials.
Arthritis, Psoriatic
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Arthritis, Psoriatic
Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
Arthritis, Psoriatic
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Arthritis, Psoriatic
Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.
Arthritis, Psoriatic
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
Arthritis, Psoriatic
Crystal structure of an apremilast ethanol hemisolvate hemihydrate solvatomorph.
Arthritis, Psoriatic
Drug survival of apremilast in a real-world setting.
Arthritis, Psoriatic
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Arthritis, Psoriatic
Emerging drugs for psoriatic arthritis.
Arthritis, Psoriatic
Genotoxic potential of a novel PDE-4B inhibitor Apremilast by chromosomal aberration and micronucleus assay in mice.
Arthritis, Psoriatic
IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.
Arthritis, Psoriatic
Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Arthritis, Psoriatic
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Arthritis, Psoriatic
Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis.
Arthritis, Psoriatic
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Arthritis, Psoriatic
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis.
Arthritis, Psoriatic
Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
Arthritis, Psoriatic
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Arthritis, Psoriatic
Off-label studies on apremilast in dermatology: a review.
Arthritis, Psoriatic
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study.
Arthritis, Psoriatic
PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase-1 by a mechanism dependent on MAP kinase phosphatase-1.
Arthritis, Psoriatic
Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
Arthritis, Psoriatic
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Arthritis, Psoriatic
Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
Arthritis, Psoriatic
Refractory palmoplantar pustulosis succesfully treated with apremilast.
Arthritis, Psoriatic
Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
Arthritis, Psoriatic
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Arthritis, Psoriatic
The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
Arthritis, Psoriatic
The Protective Effects of Apremilast Against Oxygen-Glucose Deprivation/Reperfusion (OGD/R)-Induced Inflammation and Apoptosis in Astroglia Mediated by CREB/BDNF.
Arthritis, Psoriatic
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.
Arthritis, Psoriatic
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Arthritis, Psoriatic
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Arthritis, Psoriatic
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Arthritis, Psoriatic
Work Productivity Improvement Associated With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results Of A Phase 3, Randomized, Controlled Trial.
Arthritis, Psoriatic
[Gastrointestinal side effects of apremilast : Characterization and management].
Arthritis, Rheumatoid
3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
Arthritis, Rheumatoid
Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Arthritis, Rheumatoid
Ciclamilast ameliorates adjuvant-induced arthritis in a rat model.
Arthritis, Rheumatoid
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Arthritis, Rheumatoid
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Arthritis, Rheumatoid
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Arthritis, Rheumatoid
[3',5'-cAMP phosphodiesterase inhibitors in the combined treatment of patients with rheumatoid arthritis]
Arthritis, Rheumatoid
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Asthma
(P)/(M)-corinepalensin A, a pair of axially chiral prenylated bicoumarin enantiomers with a rare C-5C-5' linkage from the twigs of Coriaria nepalensis.
Asthma
3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
Asthma
Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.
Asthma
?2-Agonists upregulate PDE4 mRNA but not protein or activity in human airway smooth muscle cells from asthmatic and nonasthmatic volunteers.
Asthma
A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma.
Asthma
A Novel Heterodimer from Crotalaria ferruginea.
Asthma
Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats.
Asthma
Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Asthma
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Asthma
Analyses of shared genetic factors between asthma and obesity in children.
Asthma
Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients.
Asthma
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.
Asthma
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Asthma
Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.
Asthma
Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Asthma
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Asthma
Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma.
Asthma
Constitutively Active Signaling by the G Protein ??-Subunit Mediates Intrinsically Increased Phosphodiesterase-4 Activity in Human Asthmatic Airway Smooth Muscle Cells.
Asthma
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Asthma
Current and emerging therapies for the management of chronic inflammation in asthma.
Asthma
Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study.
Asthma
Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.
Asthma
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Asthma
Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor.
Asthma
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
Asthma
Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Asthma
Effects of inhaled glaucine on pulmonary responses to antigen in sensitized guinea pigs.
Asthma
Effects of KF19514, a Phosphodiesterase 4 and 1 Inhibitor, on Bronchial Inflammation and Remodeling in a Murine Model of Chronic Asthma.
Asthma
Effects of phosphodiesterase 4 inhibitor on cough response in guinea pigs sensitized and challenged with ovalbumin.
Asthma
Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis.
Asthma
Efficacy and safety of roflumilast in the treatment of asthma.
Asthma
Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).
Asthma
Electrochemical Behavior and Square-Wave Stripping Voltammetric Determination of Roflumilast in Pharmaceutical Dosage Forms.
Asthma
Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene.
Asthma
Identification and Characterization of Baicalin as a Phosphodiesterase 4 Inhibitor.
Asthma
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats.
Asthma
Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages.
Asthma
Investigating the role of N-terminal domain in phosphodiesterase 4B-inhibition by molecular dynamics simulation.
Asthma
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
Asthma
Lysoquinone-TH1, a New Polyphenolic Tridecaketide Produced by Expressing the Lysolipin Minimal PKS II in Streptomyces albus.
Asthma
Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.
Asthma
Natural phosphodiesterase-4 (PDE4) inhibitors from Crotalaria ferruginea.
Asthma
New advances and potential therapies for the treatment of asthma.
Asthma
Novel signal transduction modulators for the treatment of airway diseases.
Asthma
Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
Asthma
Pharmacology of a novel, orally active PDE4 inhibitor.
Asthma
Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors.
Asthma
Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
Asthma
Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma.
Asthma
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Asthma
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Asthma
Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?
Asthma
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Asthma
Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by ?2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice.
Asthma
Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.
Asthma
Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Asthma
Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
Asthma
Phosphodiesterase 4B is essential for T(h)2-cell function and development of airway hyperresponsiveness in allergic asthma.
Asthma
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Asthma
Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?
Asthma
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Asthma
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Asthma
Practical enantioselective process for a chiral phosphodiesterase-4 inhibitor.
Asthma
Prenylated Coumarins: Natural Phosphodiesterase-4 Inhibitors from Toddalia asiatica.
Asthma
Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
Asthma
Production and characterization of pharmacologically active recombinant human phosphodiesterase 4B in Dictyostelium discoideum.
Asthma
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.
Asthma
Psiguajadials A-K: Unusual Psidium Meroterpenoids as Phosphodiesterase-4 Inhibitors from the Leaves of Psidium guajava.
Asthma
PTTG1IP and MAML3, novel genomewide association study genes for severity of hyperresponsiveness in adult asthma.
Asthma
Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.
Asthma
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Asthma
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma.
Asthma
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Asthma
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
Asthma
Selaginpulvilins A-D, new phosphodiesterase-4 inhibitors with an unprecedented skeleton from Selaginella pulvinata.
Asthma
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Asthma
Single-dose pharmacokinetics of roflumilast in children and adolescents.
Asthma
Structure Based Design of Selective Phosphodiesterase 4B Inhibitors Based on Ginger Phenolic Compounds.
Asthma
Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Asthma
Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design.
Asthma
Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.
Asthma
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Asthma
Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Asthma
The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma.
Asthma
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.
Asthma
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
Asthma
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
Asthma
The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
Asthma
The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Asthma
The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs.
Asthma
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
Asthma
The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys.
Asthma
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
Asthma
Treating asthma in the new millennium.
Asthma
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Asthma
Upregulation of phosphodiesterase-4 in the lung of allergic rats.
Asthma, Exercise-Induced
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
Atherosclerosis
Associations between SNP83 of phosphodiesterase 4D gene and carotid atherosclerosis in a southern Chinese Han population: a case-control study.
Atherosclerosis
Phosphodiesterase 4 D gene polymorphism in relation to intracranial and extracranial atherosclerosis in ischemic stroke.
Atherosclerosis
Phosphodiesterase 4D Single Nucleotide Polymorphism 83 and Cognitive Dysfunction in Carotid Endarterectomy Patients.
Atherosclerosis
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
Autoimmune Diseases
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Autoimmune Diseases
Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases.
Axial Spondyloarthritis
Axial spondyloarthritis: is there a treatment of choice?
Behcet Syndrome
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Behcet Syndrome
Apremilast in the Management of Disseminated Granuloma Annulare.
Bone Diseases, Metabolic
Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models.
Bone Resorption
Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.
Brain Diseases
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
Brain Diseases
Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET.
Brain Edema
Decreased adenosine cyclic 3',5'-monophosphate phosphodiesterase activity in rat brain following triethyltin intoxication.
Brain Injuries
Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders.
Brain Injuries
Improved sensorimotor function by rolipram following focal cerebral ischemia in rats.
Brain Injuries
Phosphodiesterase-4 inhibition confers a neuroprotective efficacy against early brain injury following experimental subarachnoid hemorrhage in rats by attenuating neuronal apoptosis through the SIRT1/Akt pathway.
Brain Injuries
Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.
Brain Injuries
Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.
Brain Injuries, Traumatic
Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor.
Brain Injuries, Traumatic
Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.
Brain Injuries, Traumatic
Tumor Necrosis Factor ? as a Potential Mediator of the Effects of Phosphodiesterase 4B Inhibition on Cognition after Traumatic Brain Injury.
Brain Ischemia
Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2/HO-1 pathway.
Brain Ischemia
Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3?-mediated oxidative stress and IRE1?/TRAF2/JNK pathway.
Brain Ischemia
Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia.
Brain Neoplasms
Phosphodiesterase-4 inhibition and brain tumor growth.
Brain Neoplasms
Targeted activation of PKA and Epac promotes glioblastoma regression in vitro.
Brain Neoplasms
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Breast Neoplasms
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Breast Neoplasms
Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility.
Bronchial Spasm
Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
Bronchiolitis
Anti-proliferative properties of the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for treatment of obliterative bronchiolitis in heterotopic rat allografts.
Bronchitis, Chronic
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Bronchitis, Chronic
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation.
Bronchitis, Chronic
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Bronchitis, Chronic
Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.
Bronchitis, Chronic
Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Bronchitis, Chronic
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Bronchitis, Chronic
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting ?2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Bronchitis, Chronic
Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Bronchitis, Chronic
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study.
Bronchitis, Chronic
Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.
Bronchitis, Chronic
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Bronchitis, Chronic
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Bronchitis, Chronic
Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences.
Bronchitis, Chronic
The clinical and economic burden of chronic obstructive pulmonary disease in the USA.
Carcinogenesis
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Carcinogenesis
Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4.
Carcinogenesis
Effect of phosphodiesterase antagonists on glucocorticoid mediated growth inhibition in murine skin cell lines.
Carcinoma
7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine, a potent inhibitor of cAMP-specific phosphodiesterase, enhancing nuclear protein binding to the CRE consensus sequence in human tumour cells.
Carcinoma
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
Carcinoma
PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway.
Carcinoma
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.
Carcinoma
Triazole-Pyridine Dicarbonitrile Targets Phosphodiesterase 4 to Induce Cytotoxicity in Lung Carcinoma Cells.
Carcinoma, Hepatocellular
Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
[Concentration and metabolism of cyclic AMP during the early stages of hepatoma 22a growth]
Carcinoma, Renal Cell
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
Cardiomegaly
AKAP signaling complexes: getting to the heart of the matter.
Cardiomyopathy, Restrictive
Epigenetic regulation of phosphodiesterase 4d in restrictive cardiomyopathy mice with cTnI mutations.
Cardiovascular Diseases
Candidate gene analysis in the São Paulo Epidemiologic Sleep Study (EPISONO) shows an association of variant in PDE4D and sleepiness.
Cardiovascular Diseases
Inhibition of PDE4 by low doses of rolipram induces changes in lipid and protein components of mice heart.
Carotid Artery Diseases
Associations between SNP83 of phosphodiesterase 4D gene and carotid atherosclerosis in a southern Chinese Han population: a case-control study.
Carotid Artery Diseases
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Carotid Artery Diseases
Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
Carotid Artery Thrombosis
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Central Nervous System Diseases
Phosphodiesterase Type 4 Inhibition in CNS Diseases.
Central Nervous System Diseases
The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion.
Cerebral Infarction
A meta-analysis of PDE-gene polymorphism and cerebral infarction risk.
Cerebral Infarction
Correlation between the single nucleotide polymorphisms of the human phosphodiesterase 4D gene and the risk of cerebral infarction in the Uygur and Han ethnic groups of Xinjiang, China.
Cerebral Infarction
Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study.
Cerebrovascular Disorders
Association between PDE4D gene and ischemic stroke: recent advancements.
Cerebrovascular Disorders
PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden.
Cholera
Characterization of the yeast low Km cAMP-phosphodiesterase with cAMP analogues. Applications in mammalian cells that express the yeast PDE2 gene.
Cholera
Cyclic AMP responses are suppressed in mammalian cells expressing the yeast low Km cAMP-phosphodiesterase gene.
Cholera
Decreased phosphodiesterase activity in cholera toxin-induced hypersecretion in suckling rats.
Cholestasis
Silibinin prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: possible involvement of cAMP.
Chorioamnionitis
Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits.
Chorioamnionitis
Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
Colitis
Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis.
Colitis
The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice.
Colitis, Ulcerative
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
Colitis, Ulcerative
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients with Active Ulcerative Colitis.
Colitis, Ulcerative
Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Colitis, Ulcerative
Tetomilast.
Colonic Neoplasms
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Colonic Neoplasms
MiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells.
Colonic Neoplasms
The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.
Colorectal Neoplasms
Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD-1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway.
Colorectal Neoplasms
Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Colorectal Neoplasms
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia.
Colorectal Neoplasms
Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture.
Colorectal Neoplasms
The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer.
Coronary Disease
Features of coronary heart disease development in emergency workers of the Chornobyl accident depending on the action of radiation and non radiation risk factors and genotypes of single nucleotide polymorphism rs966221 of phosphodiesterase 4D gene.
Coronary Disease
GENDER DISPARITIES OF CIRCULATORY DISEASE PROGRESS IN THE CHORNOBYL ACCIDENT CLEAN-UP WORKERS AND PHOSPHODIESTERASE 4D GENE rs966221 POLYMORPHISM.
Coronary Disease
Structural and functional state of heart left ventricle depending on polymorphism rs966221 phosphodiesterase 4D gene in emergency workers of the Chornobyl NPP suffering from coronary heart disease.
Cough
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Cough
Effects of phosphodiesterase 4 inhibitor on cough response in guinea pigs sensitized and challenged with ovalbumin.
COVID-19
Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
COVID-19
Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients.
COVID-19
PdCl2-catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor.
COVID-19
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.
COVID-19
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
Cryptorchidism
Expression of Phosphodiesterase 4B cAMP-Specific Gene in Subjects With Cryptorchidism and Down's Syndrome.
Cryptorchidism
Surgically induced cryptorchidism-related degenerative changes in spermatogonia are associated with loss of cyclic adenosine monophosphate-dependent phosphodiesterases type 4 in abdominal testes of rats.
Cystitis
Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats.
Cysts
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.
Dementia
Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia.
Demyelinating Diseases
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Demyelinating Diseases
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Dermatitis
Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
Dermatitis
ASB16165, a phosphodiesterase 7A inhibitor, reduces cutaneous TNF-alpha level and ameliorates skin edema in phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation model in mice.
Dermatitis
AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
Dermatitis
Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Dermatitis
Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Dermatitis
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Dermatitis
Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis.
Dermatitis
Imperatorin Alleviates Psoriasiform Dermatitis by Blocking Neutrophil Respiratory Burst, Adhesion, and Chemotaxis Through Selective Phosphodiesterase 4 Inhibition.
Dermatitis
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Dermatitis, Allergic Contact
A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Dermatitis, Allergic Contact
Effects of cilomilast on dendritic cell function in contact sensitivity and dendritic cell migration through skin.
Dermatitis, Atopic
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Dermatitis, Atopic
2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis.
Dermatitis, Atopic
A dried blood spot assay with UPLC-MS/MS for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human blood.
Dermatitis, Atopic
A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Dermatitis, Atopic
A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Dermatitis, Atopic
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults.
Dermatitis, Atopic
Advances in the understanding and treatment of atopic dermatitis.
Dermatitis, Atopic
An assessment of the genetic toxicology of novel boron-containing therapeutic agents.
Dermatitis, Atopic
Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Dermatitis, Atopic
Application of phosphodiesterase 4 inhibitor for atopic dermatitis.
Dermatitis, Atopic
Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Dermatitis, Atopic
Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis.
Dermatitis, Atopic
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Dermatitis, Atopic
Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Dermatitis, Atopic
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
Dermatitis, Atopic
Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Dermatitis, Atopic
Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Dermatitis, Atopic
Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Dermatitis, Atopic
Cyclic AMP-phosphodiesterase activity and histamine release in cord blood leukocyte preparations.
Dermatitis, Atopic
Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
Dermatitis, Atopic
Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double-blind, vehicle-controlled trial.
Dermatitis, Atopic
Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
Dermatitis, Atopic
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
Dermatitis, Atopic
Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.
Dermatitis, Atopic
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Dermatitis, Atopic
Effect of adrenaline and glucocorticoids on monocyte cAMP-specific phosphodiesterase (PDE4) in a monocytic cell line.
Dermatitis, Atopic
Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
Dermatitis, Atopic
Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
Dermatitis, Atopic
Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
Dermatitis, Atopic
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
Dermatitis, Atopic
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Dermatitis, Atopic
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Dermatitis, Atopic
Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study.
Dermatitis, Atopic
Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.
Dermatitis, Atopic
Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
Dermatitis, Atopic
Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2.
Dermatitis, Atopic
Histamine up-regulates phosphodiesterase IV activity in U-937 cells through H2 receptor stimulation and cAMP increase.
Dermatitis, Atopic
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
Dermatitis, Atopic
In Vitro Skin Retention of Crisaborole after Topical Application.
Dermatitis, Atopic
Intracellular 3',5'-adenosine cyclic monophosphate level regulates house dust mite-induced interleukin-13 production by T cells from mite-sensitive patients with atopic dermatitis.
Dermatitis, Atopic
Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
Dermatitis, Atopic
Off-Label Therapeutic Potential of Crisaborole.
Dermatitis, Atopic
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
Dermatitis, Atopic
Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
Dermatitis, Atopic
Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
Dermatitis, Atopic
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
Dermatitis, Atopic
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Dermatitis, Atopic
Phosphodiesterase 4D, miR-203 and selected cytokines in the peripheral blood are associated with canine atopic dermatitis.
Dermatitis, Atopic
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Dermatitis, Atopic
Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
Dermatitis, Atopic
Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Dermatitis, Atopic
Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
Dermatitis, Atopic
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to?24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Dermatitis, Atopic
Soft drugs for dermatological applications: recent trends.
Dermatitis, Atopic
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Dermatitis, Atopic
The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis.
Dermatitis, Atopic
Topical Agents for the Treatment of Atopic Dermatitis
Dermatitis, Atopic
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Dermatitis, Atopic
Treatment of psoriasis with crisaborole.
Dermatitis, Atopic
Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
Dermatitis, Atopic
Validation of a UPLC-MS/MS method for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human plasma.
Dermatitis, Atopic
[What's new in pediatric dermatology?]
Dermatitis, Phototoxic
Phosphodiesterase 4B plays a role in benzophenone-3-induced phototoxicity in normal human keratinocytes.
Diabetes Insipidus, Nephrogenic
Dynamics of nucleotides in distal nephron of mice with nephrogenic diabetes insipidus.
Diabetes Insipidus, Nephrogenic
Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus.
Diabetes Mellitus
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Diabetes Mellitus
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Diabetes Mellitus, Type 1
An inflammatory gene-expression fingerprint in monocytes of autoimmune thyroid disease patients.
Diabetes Mellitus, Type 2
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Diabetic Nephropathies
Protective effect of a novel phosphodiesterase 4 selective inhibitor, compound A, in diabetic nephropathy model mice.
Diabetic Neuropathies
Low concentration of Bupivacaine ameliorates painful diabetic neuropathy by mediating miR-23a/PDE4B axis in microglia.
Disorders of Excessive Somnolence
Erratum to "The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease" [Park. Relat. Disord. 77C (2021) 163-169/3948].
Disorders of Excessive Somnolence
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease.
Down Syndrome
Expression of Phosphodiesterase 4B cAMP-Specific Gene in Subjects With Cryptorchidism and Down's Syndrome.
Dyslexia
A Cohort of Balanced Reciprocal Translocations Associated with Dyslexia: Identification of Two Putative Candidate Genes at DYX1.
Dyspnea
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Ectropion
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
Embolic Stroke
Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort.
Encephalomyelitis
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
Encephalomyelitis
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
Encephalomyelitis
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Encephalomyelitis
Peripheral Phosphodiesterase 4 Inhibition Produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) Prevents Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse.
Encephalomyelitis
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Encephalomyelitis
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
Encephalomyelitis, Autoimmune, Experimental
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
Encephalomyelitis, Autoimmune, Experimental
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Peripheral Phosphodiesterase 4 Inhibition Produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) Prevents Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse.
Encephalomyelitis, Autoimmune, Experimental
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Encephalomyelitis, Autoimmune, Experimental
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis.
Endometrial Neoplasms
The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
Endotoxemia
Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.
Endotoxemia
Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation.
Endotoxemia
Rolipram Attenuates Bile Duct Ligation-Induced Liver Injury in Rats: A Potential Pathogenic Role of PDE4.
Eosinophilia
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Epilepsy
PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study.
Erectile Dysfunction
Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.
Fetal Alcohol Spectrum Disorders
Phosphodiesterase type 4 inhibition does not restore ocular dominance plasticity in a ferret model of fetal alcohol spectrum disorders.
Fetal Death
PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation.
Fibrosarcoma
Enhancement of the relative uptake of 18F-FDG in mouse fibrosarcoma by rolipram.
Fibrous Dysplasia, Polyostotic
PET imaging of phosphodiesterase-4 identifies affected dysplastic bone in McCune-Albright syndrome, a genetic mosaic disorder.
Fragile X Syndrome
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
Gastroparesis
PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
Glioblastoma
Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.
Glioblastoma
PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells.
Glioblastoma
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Glioblastoma
The Role of Protein Kinase B Signaling Pathway in Anti-Cancer Effect of Rolipram on Glioblastoma Multiforme: An In Vitro Study.
Glioblastoma
Theobromine, the Primary Methylxanthine Found in Theobroma cacao, Prevents Malignant Glioblastoma Proliferation by Negatively Regulating Phosphodiesterase-4, Extracellular Signal-regulated Kinase, Akt/mammalian Target of Rapamycin Kinase, and Nuclear Factor-Kappa B.
Glioma
Adsorption of miR-218 by lncRNA HOTAIR regulates PDE7A and affects glioma cell proliferation, invasion, and apoptosis.
Glioma
BDNF and PDE4, but not the GRPR, Regulate Viability of Human Medulloblastoma Cells.
Glioma
Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.
Glioma
Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Glioma
Intracranial glioma xenograft model rapidly reestablishes blood-brain barrier integrity for longitudinal imaging of tumor progression using fluorescence molecular tomography and contrast agents.
Graft vs Host Disease
Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice.
Graft vs Host Disease
Erratum to "Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice".
Granuloma
Selective Inhibition of PDE4 in Wistar Rats Can Lead to Dilatation in Testis, Efferent Ducts, and Epididymis and Subsequent Formation of Sperm Granulomas.
Growth Hormone-Secreting Pituitary Adenoma
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Head and Neck Neoplasms
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Hearing Loss, Sensorineural
Phosphodiesterase 4D gene polymorphisms in sudden sensorineural hearing loss.
Heart Failure
Cardiac Overexpression of PDE4B Blunts ?-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Heart Failure
Phosphodiesterase 4D and heart failure: a cautionary tale.
Heart Failure
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.
Hematologic Neoplasms
PDE4 subtypes in cancer.
Hemoglobinopathies
Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in ?-Thalassemia Intermedia: A Validation Cohort Study.
Hemorrhagic Stroke
A meta-analysis of PDE-gene polymorphism and cerebral infarction risk.
Hepatitis
Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice.
Hepatitis
Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis.
Hepatitis, Autoimmune
PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.
Herpes Simplex
Methodology and problems of protein-ligand docking: case study of dihydroorotate dehydrogenase, thymidine kinase, and phosphodiesterase 4.
Herpes Zoster
Studies on cyclic nucleotides in the adrenal gland. VIII. Effects of angiotensin on adenosine 3',5'-monophosphate and steroidogenesis in the adrenal cortex.
HIV Infections
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
Huntington Disease
Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.
Hyperalgesia
Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.
Hyperalgesia
Rolipram, a Selective Phosphodiesterase 4 Inhibitor, Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain through Inhibition of Inflammatory Cytokines in the Dorsal Root Ganglion.
Hypercalcemia
AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.
Hypersensitivity
Neonatal leukocyte cAMP-phosphodiesterase determination is not suitable for allergy prediction.
Hypersensitivity
Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction.
Hypersensitivity
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Hypertension
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Hypertension
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Hypertension
Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model.
Hypertension
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.
Hypertension
Regulation of renovascular adenosine 3',5'-cyclic monophosphate in spontaneously hypertensive rats.
Hypertension, Pulmonary
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
Hypertension, Pulmonary
Effects of Roflumilast, a Phosphodiesterase-4 Inhibitor on Hypoxia- and Monocrotaline-induced Pulmonary Hypertension in Rats.
Hyperthyroidism
Influence of exogenous ATP on blood sugar, serum insulin and serum free fatty acids in short-term experimental hyperthyroid dogs and in euthyroid controls.
Hypophosphatemia, Familial
Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo.
Hypothyroidism
Low particulate type IV phosphodiesterase activity in hypothyroid rat atria.
Idiopathic Pulmonary Fibrosis
Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.
Infarction, Middle Cerebral Artery
The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion.
Infections
Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.
Infections
Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.
Infections
Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits.
Infections
Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update.
Infections
cAMP-specific phosphodiesterase TbPDE1 is not essential in Trypanosoma brucei in culture or during midgut infection of tsetse flies.
Infections
Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4.
Infections
Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells.
Infections
Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.
Infections
Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication.
Infections
Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.
Infections
The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence.
Infections
[Acute exacerbation in COPD and asthma].
Infertility, Female
Conditional rescue of the dunce learning/memory and female fertility defects with Drosophila or rat transgenes.
Inflammatory Bowel Diseases
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Inflammatory Bowel Diseases
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Inflammatory Bowel Diseases
Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Inflammatory Bowel Diseases
Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Inflammatory Bowel Diseases
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Inflammatory Bowel Diseases
Tetomilast: new promise for phosphodiesterase-4 inhibitors?
Inflammatory Bowel Diseases
TGF-? activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Insulin Resistance
Reduced adiposity and high fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.
Insulinoma
PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C.
Intracranial Aneurysm
[Genetics of cerebral vascular accidents]
Ischemic Stroke
A large-sample assessment of possible association between ischaemic stroke and rs12188950 in the PDE4D gene.
Ischemic Stroke
A meta-analysis of PDE-gene polymorphism and cerebral infarction risk.
Ischemic Stroke
Association between phosphodiesterase 4D (PDE4D) SNP 87 and ischemic stroke: a meta-analysis.
Ischemic Stroke
Association between phosphodiesterase 4D gene and ischaemic stroke.
Ischemic Stroke
Association between phosphodiesterase 4D polymorphism SNP83 and ischemic stroke.
Ischemic Stroke
Association of a Genetic Variant in the ALOX5AP with Higher Risk of Ischemic Stroke: A Case-Control, Meta-Analysis and Functional Study.
Ischemic Stroke
Association of PDE4D and IL-1 gene polymorphism with ischemic stroke in a Han Chinese population.
Ischemic Stroke
Association of phosphodiesterase 4D gene and interleukin-6 receptor gene polymorphisms with ischemic stroke in a Chinese hypertensive population.
Ischemic Stroke
Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population.
Ischemic Stroke
Association of phosphodiesterase 4D gene with ischemic stroke in a Pakistani population.
Ischemic Stroke
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Ischemic Stroke
Association of Phosphodiesterase 4D with ischemic stroke: a population-based case-control study.
Ischemic Stroke
Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort.
Ischemic Stroke
Effects of PDE4 pathway inhibition in rat experimental stroke.
Ischemic Stroke
Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort.
Ischemic Stroke
FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3?/ ?-catenin signaling pathway.
Ischemic Stroke
Genetic variants of phosphodiesterase 4D gene are associated with an enhanced risk for ischemic stroke in young Chinese population.
Ischemic Stroke
Genetics of ischemic stroke.
Ischemic Stroke
Impact of the PDE4D gene polymorphism and additional SNP-SNP and gene-smoking interaction on ischemic stroke risk in Chinese Han population.
Ischemic Stroke
Independent ischemic stroke risk factors in older Americans: a systematic review.
Ischemic Stroke
Ischaemic stroke in hypertensive patients is associated with variations in the PDE4D genome region.
Ischemic Stroke
Ischemic stroke risk in a southeastern Chinese population: Insights from 5-lipoxygenase activating protein and phosphodiesterase 4D single-nucleotide polymorphisms.
Ischemic Stroke
Meta-analysis of association between variation in the PDE4D gene and ischemic cerebral infarction risk in Asian populations.
Ischemic Stroke
No Association Between Single-Nucleotide Polymorphism 56 (SNP56) in Phosphodiesterase 4D (PDE4D) Gene and Susceptibility to Ischemic Stroke: A Meta-Analysis of 15 Studies.
Ischemic Stroke
Phosphodiesterase 4 D gene polymorphism in relation to intracranial and extracranial atherosclerosis in ischemic stroke.
Ischemic Stroke
Phosphodiesterase 4D (PDE4D) gene variants and the risk of ischemic stroke in a South Indian population.
Ischemic Stroke
Phosphodiesterase 4D and 5-lipoxygenase activating protein genes and risk of ischemic stroke in Sardinians.
Ischemic Stroke
Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.
Ischemic Stroke
Phosphodiesterase 4D gene and risk of noncardiogenic ischemic stroke in a Korean population.
Ischemic Stroke
Phosphodiesterase 4D gene polymorphisms in sudden sensorineural hearing loss.
Ischemic Stroke
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Ischemic Stroke
Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study.
Ischemic Stroke
Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke.
Ischemic Stroke
Phosphodiesterase4D (PDE4D)--A risk factor for atrial fibrillation and stroke?
Ischemic Stroke
Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis.
Ischemic Stroke
Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation.
Ischemic Stroke
Relationship of phosphodiesterase 4D (PDE4D) gene polymorphisms with risk of ischemic stroke: a hospital based case-control study.
Ischemic Stroke
Rolipram stimulates angiogenesis and attenuates neuronal apoptosis through the cAMP/cAMP-responsive element binding protein pathway following ischemic stroke in rats.
Ischemic Stroke
Sex-dependent association of phosphodiesterase 4D gene polymorphisms with ischemic stroke in Henan Han population.
Ischemic Stroke
Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke.
Ischemic Stroke
The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.
Ischemic Stroke
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
Ischemic Stroke
The phosphodiesterase 4D gene for early onset ischemic stroke among normotensive patients.
Ischemic Stroke
The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
Ischemic Stroke
The Siblings With Ischemic Stroke Study (SWISS): A Progress Report.
Ischemic Stroke
Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?
Ischemic Stroke
[Analysis of the polymorphic variants of the PDE4D gene in patients with acute stroke in the Moldavian population].
Ischemic Stroke
Investigation of single nucleotide polymorphisms in phosphodiesterase 4D gene in Mongol and Han patients with ischemic stroke in Inner Mongolia.
Kidney Diseases
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Kidney Diseases, Cystic
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.
Kidney Neoplasms
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
Latent Autoimmune Diabetes in Adults
An inflammatory gene-expression fingerprint in monocytes of autoimmune thyroid disease patients.
Learning Disabilities
New Selective Phosphodiesterase 4D Inhibitors Differently Acting on Long, Short, and Supershort Isoforms.
Leukemia
Bresol inhibits phosphodiesterase 4 gene expression and modulates the levels of select mediators of inflammation in human monocytic cells.
Leukemia
Synergistic effect of caffeine and glucocorticoids on expression of surfactant protein B (SP-B) mRNA.
Leukemia
Systematic identification of regulatory variants associated with cancer risk.
Leukemia
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.
Leukemia, Lymphocytic, Chronic, B-Cell
Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.
Leukemia, Lymphocytic, Chronic, B-Cell
PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Leukemia, Myeloid, Acute
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Lichen Planus, Oral
Expression and significance of phosphodiesterase 4B gene in peripheral blood of patients with oral lichen planus.
Liver Cirrhosis
Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition.
Liver Diseases, Alcoholic
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease.
Liver Diseases, Alcoholic
Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
Lung Diseases
Anti-proliferative properties of the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for treatment of obliterative bronchiolitis in heterotopic rat allografts.
Lung Diseases
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
Lung Diseases
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Lung Diseases
Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor.
Lung Diseases
Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Lung Diseases
Phosphodiesterase-4 inhibitor therapy for lung diseases.
Lung Diseases
Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Lung Diseases
Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge.
Lung Diseases, Obstructive
A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
Lung Diseases, Obstructive
Investigating the role of N-terminal domain in phosphodiesterase 4B-inhibition by molecular dynamics simulation.
Lung Diseases, Obstructive
[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease]
Lung Injury
Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.
Lung Injury
Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
Lung Injury
Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs.
Lung Injury
Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats.
Lung Injury
Osthol attenuates neutrophilic oxidative stress and hemorrhagic shock-induced lung injury via inhibition of phosphodiesterase 4.
Lung Injury
Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.
Lung Injury
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Lung Injury
Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
Lung Injury
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Lung Injury
Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
Lung Injury
Suppression of neutrophilic inflammation can be modulated by the droplet size of anti-inflammatory nanoemulsions.
Lung Injury
Use of a Soluble Epoxide Hydrolase Inhibitor in Smoke-Induced Chronic Obstructive Pulmonary Disease.
Lung Neoplasms
PDE4 subtypes in cancer.
Lung Neoplasms
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Lymphoma
Cyclic adenosine monophosphate signal pathway in targeted therapy of lymphoma.
Lymphoma
Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
Lymphoma
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
Lymphoma
High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma.
Lymphoma
MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
Lymphoma
[Expression of Cyclic Nucleotide Phosphodiesterase 7B in Patients with Mantle Cell Lymphoma and Its Prognostic Significance.]
Lymphoma, B-Cell
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Lymphoma, B-Cell
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
Lymphoma, B-Cell
MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
Lymphoma, B-Cell
Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Lymphoma, B-Cell
Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas.
Lymphoma, B-Cell
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Lymphoma, Large B-Cell, Diffuse
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Lymphoma, Mantle-Cell
High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma.
Lymphoma, Mantle-Cell
[Expression of Cyclic Nucleotide Phosphodiesterase 7B in Patients with Mantle Cell Lymphoma and Its Prognostic Significance.]
Medulloblastoma
Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma.
Medulloblastoma
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Melanoma
A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.
Melanoma
Activation of ?2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.
Melanoma
Debenzylative Cycloetherification as a Synthetic Tool in the Diastereoselective Synthesis of 3,6-Disubstituted Hexahydro-2H-furo[3,2-b]pyrroles, PDE1 Enzyme Inhibitors with an Antiproliferative Effect on Melanoma Cells.
Melanoma
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
Melanoma
Phosphodiesterase 4 regulates the migration of B16-F10 melanoma cells.
Memory Disorders
Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System.
Memory Disorders
Inhibiting PDE7A Enhances the Protective Effects of Neural Stem Cells on Neurodegeneration and Memory Deficits in Sevoflurane-Exposed Mice.
Memory Disorders
Inhibition of phosphodiesterase-4 reverses memory deficits produced by A?25-35 or A?1-40 peptide in rats.
Memory Disorders
Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Memory Disorders
Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats.
Memory Disorders
Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer's disease.
Memory Disorders
RNA Interference-Mediated Knockdown of Long-Form Phosphodiesterase-4D (PDE4D) Enzyme Reverses Amyloid-?42-Induced Memory Deficits in Mice.
Memory Disorders
Rolipram rescues memory consolidation deficits caused by sleep deprivation: Implication of the cAMP/PKA and cAMP/Epac pathways.
Memory Disorders
The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss.
Memory Disorders
The phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer's disease: a preclinical study in APP/PS1 transgenic mice.
Memory Disorders
Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.
Metabolic Diseases
Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases.
Mouth Neoplasms
Ligand/PTC-free intramolecular Heck reaction: synthesis of pyrroloquinoxalines and their evaluation against PDE4/luciferase/oral cancer cell growth in vitro and zebrafish in vivo.
Multiple Sclerosis
InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.
Multiple Sclerosis
Peripheral Phosphodiesterase 4 Inhibition Produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) Prevents Experimental Autoimmune Encephalomyelitis.
Multiple Sclerosis
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Multiple Sclerosis
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Multiple Sclerosis
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Multiple Sclerosis
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Muscular Atrophy
Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy.
Muscular Atrophy
Phosphodiesterase 4B knockout prevents skeletal muscle atrophy in rats with burn injury.
Muscular Dystrophy, Duchenne
Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Myelodysplastic Syndromes
CC-1088 Celgene.
Myocardial Infarction
A haplotype of the phosphodiesterase 4D (PDE4D) gene is associated with myocardial infarction and with cardiometabolic parameters: the GEA study.
Myocardial Infarction
Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury.
Myocardial Infarction
[Association of rs966221 phosphodiesterase 4D gene's polymorphism with risk of myocardial infarction].
Myoclonus
PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study.
Myoma
[Effect of 17 beta-estradiol on 3',5'-cyclic AMP phosphodiesterase of uterine tissues in myoma]
Myopia
Declines in PDE4B activity promote myopia progression through downregulation of scleral collagen expression.
Nasopharyngeal Carcinoma
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Neoplasm Metastasis
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Neoplasm Metastasis
Identification of PDE7B as a Potential Core Gene Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.
Neoplasm Metastasis
MiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells.
Neoplasms
7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine, a potent inhibitor of cAMP-specific phosphodiesterase, enhancing nuclear protein binding to the CRE consensus sequence in human tumour cells.
Neoplasms
A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity.
Neoplasms
Advances in the Development of Phosphodiesterase-4 Inhibitors.
Neoplasms
Apremilast and its role in psoriatic arthritis.
Neoplasms
Apremilast in dermatology: A review of literature.
Neoplasms
Attenuation of cAMP-mediated responses in MA-10 Leydig tumor cells by genetic manipulation of a cAMP-phosphodiesterase.
Neoplasms
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Neoplasms
Candidate gene analysis in the São Paulo Epidemiologic Sleep Study (EPISONO) shows an association of variant in PDE4D and sleepiness.
Neoplasms
Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor.
Neoplasms
Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Neoplasms
Correction: Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells.
Neoplasms
Cyclic AMP-binding proteins: inverse relationship with estrogen-receptors in hormone-dependent mammary tumor regression.
Neoplasms
Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies.
Neoplasms
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
Neoplasms
Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Neoplasms
Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
Neoplasms
Enhancement of the relative uptake of 18F-FDG in mouse fibrosarcoma by rolipram.
Neoplasms
Future therapeutic treatment of COPD: struggle between oxidants and cytokines.
Neoplasms
Gene expression changes in peripheral blood mononuclear cells during measles virus infection.
Neoplasms
Gene-set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
Neoplasms
Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells.
Neoplasms
Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma.
Neoplasms
H-Prune through GSK-3? interaction sustains canonical WNT/?-catenin signaling enhancing cancer progression in NSCLC.
Neoplasms
High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.
Neoplasms
Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Neoplasms
Identification of Gene Loci That Overlap Between Mental Disorders and Poor Prognosis of Cancers.
Neoplasms
Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation.
Neoplasms
Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.
Neoplasms
Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Neoplasms
Intracranial glioma xenograft model rapidly reestablishes blood-brain barrier integrity for longitudinal imaging of tumor progression using fluorescence molecular tomography and contrast agents.
Neoplasms
Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.
Neoplasms
Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes.
Neoplasms
Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
Neoplasms
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Neoplasms
MiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells.
Neoplasms
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Neoplasms
Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells.
Neoplasms
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments.
Neoplasms
PDE4 subtypes in cancer.
Neoplasms
PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.
Neoplasms
PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells.
Neoplasms
Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane.
Neoplasms
Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.
Neoplasms
Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase.
Neoplasms
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Neoplasms
Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
Neoplasms
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Neoplasms
Phosphodiesterase sequence variants may predispose to prostate cancer.
Neoplasms
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Neoplasms
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia.
Neoplasms
Plasma cAMP and cAMP-phosphodiesterase (PDE) levels in cancer patients before and after surgery.
Neoplasms
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Neoplasms
Quinolines: a new hope against inflammation.
Neoplasms
Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
Neoplasms
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Neoplasms
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Neoplasms
Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
Neoplasms
Rolipram Attenuates Bile Duct Ligation-Induced Liver Injury in Rats: A Potential Pathogenic Role of PDE4.
Neoplasms
Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B cell malignancies.
Neoplasms
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Neoplasms
Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation.
Neoplasms
Signaling of the direction-sensing FAK/RACK1/PDE4D5 complex to the small GTPase Rap1.
Neoplasms
siRNA-mediated silencing of phosphodiesterase 4B expression affects the production of cytokines in endotoxin-stimulated primary cultured microglia.
Neoplasms
Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Neoplasms
Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12.
Neoplasms
Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.
Neoplasms
Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.
Neoplasms
Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth.
Neoplasms
Systematic identification of regulatory variants associated with cancer risk.
Neoplasms
Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Neoplasms
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
Neoplasms
The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon.
Neoplasms
The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.
Neoplasms
The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide.
Neoplasms
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Neoplasms
The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
Neoplasms
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Neoplasms
The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between Tumor necrosis factor-alpha and interleukin-10.
Neoplasms
The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
Neoplasms
Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Neoplasms
Therapy for chronic obstructive pulmonary disease in the 21st century.
Neoplasms
Tilapia hepcidin 2-3 peptide modulates lipopolysaccharide-induced cytokines and inhibits tumor necrosis factor-alpha through cyclooxygenase-2 and phosphodiesterase 4D.
Neoplasms
Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.
Neoplasms
Triazole-Pyridine Dicarbonitrile Targets Phosphodiesterase 4 to Induce Cytotoxicity in Lung Carcinoma Cells.
Neoplasms
Tumor Necrosis Factor ? as a Potential Mediator of the Effects of Phosphodiesterase 4B Inhibition on Cognition after Traumatic Brain Injury.
Neoplasms
Unconventional therapies for hidradenitis suppurativa.
Neoplasms
Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Neoplasms
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Nervous System Diseases
Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders.
Nervous System Diseases
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
Nervous System Diseases
PDE4 Inhibition by Rolipram Promotes Neuronal Differentiation in Human Bone Marrow Mesenchymal Stem Cells.
Nervous System Diseases
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Nervous System Diseases
Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Nervous System Diseases
Rapid identification of a novel phosphodiesterase 7B tracer for receptor occupancy studies using LC?MS/MS.
Nervous System Diseases
Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, A? extrusion transporter ABCB1, and reversal by PKA inhibitor H89.
Neuralgia
Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation.
Neuralgia
Rolipram, a Selective Phosphodiesterase 4 Inhibitor, Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain through Inhibition of Inflammatory Cytokines in the Dorsal Root Ganglion.
Neuralgia
The Analgesic Effect of Rolipram, a Phosphodiesterase 4 Inhibitor, on Chemotherapy-Induced Neuropathic Pain in Rats.
Neurobehavioral Manifestations
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Neuroblastoma
Induction and quantitation of the RI cAMP-binding protein in clonal mouse neuroblastoma cell lines: evidence that the increase in RI is not linked to neurite outgrowth.
Neuroblastoma
Specificity of the action of cAMP agonists in the induction of RI cAMP-binding protein in mouse neuroblastoma cells.
Neurodegenerative Diseases
Development of improved models for phosphodiesterase-4 inhibitors with a multi-conformational structure-based QSAR method.
Neurodegenerative Diseases
Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease.
Neurodegenerative Diseases
Roflumilast, a cAMP-Specific Phosphodiesterase-4 Inhibitor, Reduces Oxidative Stress and Improves Synapse Functions in Human Cortical Neurons Exposed to the Excitotoxin Quinolinic Acid.
Neuroinflammatory Diseases
Lipopolysaccharide administration in vivo induces differential expression of cAMP-specific phosphodiesterase 4B mRNA splice variants in the mouse brain.
Neuroinflammatory Diseases
Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF-?B Inhibition.
Neuroinflammatory Diseases
Overexpression of phosphodiesterase-4 subtypes involved in surgery-induced neuroinflammation and cognitive dysfunction in mice.
Neuroinflammatory Diseases
PDE4B as a microglia target to reduce neuroinflammation.
Neuroinflammatory Diseases
Phosphodiesterase 4B: Master Regulator of Brain Signaling.
Neuronal Ceroid-Lipofuscinoses
Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
Non-alcoholic Fatty Liver Disease
Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients with Nonalcoholic Steatohepatitis.
Obesity
Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity.
Obesity
Analyses of shared genetic factors between asthma and obesity in children.
Obesity
Molecular characterization of an interstitial deletion of 1p31.3 in a patient with obesity and psychiatric illness and a review of the literature.
Obesity
Reduced adiposity and high fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.
Obesity
Theobromine alleviates diet-induced obesity in mice via phosphodiesterase-4 inhibition.
Obstetric Labor, Premature
Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3',5'-monophosphate-dependent pathway.
Obstetric Labor, Premature
Uterus-relaxing effect of ?(2) -agonists in combination with phosphodiesterase inhibitors: Studies on pregnant rat in vivo and on pregnant human myometrium in vitro.
Oral Ulcer
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Oral Ulcer
Apremilast in the Management of Disseminated Granuloma Annulare.
Oral Ulcer
Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Oral Ulcer
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Osteoarthritis
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Osteoarthritis
Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
Osteosarcoma
Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Osteosarcoma
Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition.
Parkinson Disease
Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP
Parkinson Disease
Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson's disease.
Parkinson Disease
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Parkinson Disease
Phosphodiesterase 4: Rethinking cognition in Parkinson disease.
Parkinson Disease
Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats.
Parkinson Disease
Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease.
Parkinson Disease
Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease.
Parkinson Disease
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease.
Pemphigoid, Bullous
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.
Pemphigus
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.
Peripheral Vascular Diseases
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Peritonitis
Ciclamilast ameliorates adjuvant-induced arthritis in a rat model.
Pituitary Neoplasms
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Pituitary Neoplasms
Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.
Pityriasis
A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
Pityriasis
Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
Pityriasis Rubra Pilaris
A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
Pityriasis Rubra Pilaris
Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
Pneumonia
Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency.
Pneumonia
An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Pneumonia
Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.
Pneumonia
Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
Pneumonia
G Protein ??-Subunit Signaling Mediates Airway Hyperresponsiveness and Inflammation in Allergic Asthma.
Pneumonia
Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Pneumonia
Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and atopy.
Pneumonia
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Pneumonia
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
Pneumonia
Roflumilast: A Review in COPD.
Pneumonia
The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs.
Pneumonia
The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Polycystic Ovary Syndrome
Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Phosphodiesterase 4 inhibitor plus metformin is superior to metformin alone for the treatment of polycystic ovary syndrome: A rat model study.
Polydactyly
Elevated rate of DNA synthesis and its correlation to cAMP-phosphodiesterase activity during induction of polydactyly in mouse embryos heterozygous for Hemimelia-extra toe (Hmx).
Polyuria
AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.
Polyuria
Low aquaporin-2 levels in polyuric DI +/+ severe mice with constitutively high cAMP-phosphodiesterase activity.
Prolactinoma
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.
Prostatic Neoplasms
Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer.
Prostatic Neoplasms
Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance.
Prostatic Neoplasms
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Prostatic Neoplasms
Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Prostatic Neoplasms
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.
Prostatic Neoplasms
The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.
Prostatic Neoplasms
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
Prostatic Neoplasms
The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.
Prostatic Neoplasms
The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Prostatic Neoplasms
Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Proteinuria
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.
Pruritus
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Pruritus
Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Psoriasis
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Psoriasis
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Psoriasis
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
Psoriasis
Apremilast ameliorates IL-1?-induced dysfunction in epidermal stem cells.
Psoriasis
Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6.
Psoriasis
Apremilast and suicidality: a retrospective analysis of three large databases: the FAERS, EudraVigilance, and a large single-center U.S. patient population.
Psoriasis
Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic.
Psoriasis
Apremilast for psoriasis treatment.
Psoriasis
Apremilast for the management of moderate to severe plaque psoriasis.
Psoriasis
Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
Psoriasis
Apremilast in psoriasis - a prospective real-world study.
Psoriasis
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
Psoriasis
Apremilast in Refractory Alopecia Areata.
Psoriasis
Apremilast in the Management of Disseminated Granuloma Annulare.
Psoriasis
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
Psoriasis
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Psoriasis
Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.
Psoriasis
Apremilast monotherapy for palmoplantar pustulosis: Report of three cases.
Psoriasis
Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.
Psoriasis
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
Psoriasis
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Psoriasis
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Psoriasis
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials.
Psoriasis
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Psoriasis
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Psoriasis
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Psoriasis
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Psoriasis
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Psoriasis
Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Psoriasis
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
Psoriasis
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial.
Psoriasis
Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study.
Psoriasis
Development of alopecia areata during phosphodiesterase 4 inhibitor treatment for psoriasis: A case report.
Psoriasis
Drug survival of apremilast in a real-world setting.
Psoriasis
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Psoriasis
Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.
Psoriasis
Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.
Psoriasis
Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Psoriasis
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Psoriasis
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Psoriasis
Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
Psoriasis
IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.
Psoriasis
Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
Psoriasis
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Psoriasis
Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis.
Psoriasis
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Psoriasis
Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
Psoriasis
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Psoriasis
Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
Psoriasis
New and emerging therapies in psoriasis.
Psoriasis
New Oral Therapies for Psoriasis: A Comprehensive Review.
Psoriasis
New Therapies for Psoriasis.
Psoriasis
Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Psoriasis
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Psoriasis
Novel systemic therapies for the treatment of psoriasis.
Psoriasis
Off-label studies on apremilast in dermatology: a review.
Psoriasis
Oral Apremilast for the Treatment of Plaque Psoriasis.
Psoriasis
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Psoriasis
Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study.
Psoriasis
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
Psoriasis
Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Psoriasis
Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
Psoriasis
Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo.
Psoriasis
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Psoriasis
Phosphodiesterase-4 Inhibition in Psoriasis.
Psoriasis
Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.
Psoriasis
Positioning of apremilast in treatment of Behçet's disease.
Psoriasis
Real-World Experience With Apremilast in Treating Psoriasis.
Psoriasis
Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience.
Psoriasis
Real-world use of apremilast for patients with psoriasis in Japan.
Psoriasis
Refractory palmoplantar pustulosis succesfully treated with apremilast.
Psoriasis
Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis.
Psoriasis
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Psoriasis
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Psoriasis
Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
Psoriasis
Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
Psoriasis
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Psoriasis
Targeted Therapy for Pediatric Psoriasis.
Psoriasis
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Psoriasis
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Psoriasis
The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
Psoriasis
The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
Psoriasis
The Protective Effects of Apremilast Against Oxygen-Glucose Deprivation/Reperfusion (OGD/R)-Induced Inflammation and Apoptosis in Astroglia Mediated by CREB/BDNF.
Psoriasis
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios.
Psoriasis
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Psoriasis
Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.
Psoriasis
Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Psoriasis
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Psoriasis
Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
Psoriasis
Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
Psoriasis
[Gastrointestinal side effects of apremilast : Characterization and management].
Pulmonary Arterial Hypertension
Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model.
Pulmonary Arterial Hypertension
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.
Pulmonary Disease, Chronic Obstructive
(P)/(M)-corinepalensin A, a pair of axially chiral prenylated bicoumarin enantiomers with a rare C-5C-5' linkage from the twigs of Coriaria nepalensis.
Pulmonary Disease, Chronic Obstructive
3,4,5-Trihydroxycinnamic acid exerts a protective effect on pulmonary inflammation in an experimental animal model of COPD.
Pulmonary Disease, Chronic Obstructive
3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
Pulmonary Disease, Chronic Obstructive
A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
Pulmonary Disease, Chronic Obstructive
A Novel Heterodimer from Crotalaria ferruginea.
Pulmonary Disease, Chronic Obstructive
Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats.
Pulmonary Disease, Chronic Obstructive
ACP Journal Club. Review: oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD.
Pulmonary Disease, Chronic Obstructive
Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Pulmonary Disease, Chronic Obstructive
Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells.
Pulmonary Disease, Chronic Obstructive
Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Pulmonary Disease, Chronic Obstructive
An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Pulmonary Disease, Chronic Obstructive
An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Pulmonary Disease, Chronic Obstructive
Analysis of the polarization states of the alveolar macrophages in chronic obstructive pulmonary disease samples based on miRNA-mRNA network signatures.
Pulmonary Disease, Chronic Obstructive
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Pulmonary Disease, Chronic Obstructive
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.
Pulmonary Disease, Chronic Obstructive
Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism.
Pulmonary Disease, Chronic Obstructive
Benefits and harms of roflumilast in moderate to severe COPD.
Pulmonary Disease, Chronic Obstructive
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation.
Pulmonary Disease, Chronic Obstructive
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Pulmonary Disease, Chronic Obstructive
Cardiovascular Safety In Patients Receiving Roflumilast for the Treatment of Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
CC-10004 .
Pulmonary Disease, Chronic Obstructive
Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model.
Pulmonary Disease, Chronic Obstructive
Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.
Pulmonary Disease, Chronic Obstructive
Chronic obstructive pulmonary disease: emerging therapies.
Pulmonary Disease, Chronic Obstructive
Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Pulmonary Disease, Chronic Obstructive
Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Pulmonary Disease, Chronic Obstructive
Cilomilast GlaxoSmithKline.
Pulmonary Disease, Chronic Obstructive
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Pulmonary Disease, Chronic Obstructive
Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
Pulmonary Disease, Chronic Obstructive
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
Pulmonary Disease, Chronic Obstructive
Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice.
Pulmonary Disease, Chronic Obstructive
Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Pulmonary Disease, Chronic Obstructive
Common lung conditions: chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.
Pulmonary Disease, Chronic Obstructive
COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.
Pulmonary Disease, Chronic Obstructive
COPD: current therapeutic interventions and future approaches.
Pulmonary Disease, Chronic Obstructive
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Pulmonary Disease, Chronic Obstructive
Cross-talk between PKA-C? and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Pulmonary Disease, Chronic Obstructive
Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Pulmonary Disease, Chronic Obstructive
Current and emerging therapies for the management of chronic inflammation in asthma.
Pulmonary Disease, Chronic Obstructive
Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Cytokines as targets in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study.
Pulmonary Disease, Chronic Obstructive
Development of improved models for phosphodiesterase-4 inhibitors with a multi-conformational structure-based QSAR method.
Pulmonary Disease, Chronic Obstructive
Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.
Pulmonary Disease, Chronic Obstructive
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.
Pulmonary Disease, Chronic Obstructive
Direct Inhibitory Effect of the Phosphodiesterase-4 Inhibitor, Roflumilast, on Neutrophil Migration in COPD.
Pulmonary Disease, Chronic Obstructive
Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.
Pulmonary Disease, Chronic Obstructive
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Pulmonary Disease, Chronic Obstructive
Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor.
Pulmonary Disease, Chronic Obstructive
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
Pulmonary Disease, Chronic Obstructive
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Pulmonary Disease, Chronic Obstructive
Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study.
Pulmonary Disease, Chronic Obstructive
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.
Pulmonary Disease, Chronic Obstructive
Effect of roflumilast on airway remodelling in a murine model of chronic asthma.
Pulmonary Disease, Chronic Obstructive
Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide.
Pulmonary Disease, Chronic Obstructive
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
Pulmonary Disease, Chronic Obstructive
Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Pulmonary Disease, Chronic Obstructive
Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.
Pulmonary Disease, Chronic Obstructive
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
Pulmonary Disease, Chronic Obstructive
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting ?2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Pulmonary Disease, Chronic Obstructive
Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.
Pulmonary Disease, Chronic Obstructive
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.
Pulmonary Disease, Chronic Obstructive
Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis.
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Pulmonary Disease, Chronic Obstructive
Efficacy and safety of roflumilast in the treatment of asthma.
Pulmonary Disease, Chronic Obstructive
Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).
Pulmonary Disease, Chronic Obstructive
Efficiency and safety of roflumilast combined with long-acting bronchodilators on moderate-to-severe stable chronic obstructive pulmonary disease patients: a meta-analysis.
Pulmonary Disease, Chronic Obstructive
Electrochemical Behavior and Square-Wave Stripping Voltammetric Determination of Roflumilast in Pharmaceutical Dosage Forms.
Pulmonary Disease, Chronic Obstructive
Emerging drugs for the treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Emerging targets for COPD therapy.
Pulmonary Disease, Chronic Obstructive
Future directions in the pharmacologic therapy of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Future treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Future treatments for chronic obstructive pulmonary disease and its comorbidities.
Pulmonary Disease, Chronic Obstructive
Glucocorticoid Receptor ? Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Pulmonary Disease, Chronic Obstructive
GS-5759, a Bifunctional ?2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells.
Pulmonary Disease, Chronic Obstructive
How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
Pulmonary Disease, Chronic Obstructive
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study.
Pulmonary Disease, Chronic Obstructive
Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Pulmonary Disease, Chronic Obstructive
Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages.
Pulmonary Disease, Chronic Obstructive
Is there a role for antiinflammatory treatment in COPD?
Pulmonary Disease, Chronic Obstructive
Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.
Pulmonary Disease, Chronic Obstructive
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
Pulmonary Disease, Chronic Obstructive
Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey.
Pulmonary Disease, Chronic Obstructive
Lysoquinone-TH1, a New Polyphenolic Tridecaketide Produced by Expressing the Lysolipin Minimal PKS II in Streptomyces albus.
Pulmonary Disease, Chronic Obstructive
Mini Review: Chronic obstructive pulmonary disease, its new drug treatments and strategies: A review.
Pulmonary Disease, Chronic Obstructive
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.
Pulmonary Disease, Chronic Obstructive
Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.
Pulmonary Disease, Chronic Obstructive
New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine.
Pulmonary Disease, Chronic Obstructive
No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
Pulmonary Disease, Chronic Obstructive
Novel signal transduction modulators for the treatment of airway diseases.
Pulmonary Disease, Chronic Obstructive
Optimal treatment sequence in COPD: Can a consensus be found?
Pulmonary Disease, Chronic Obstructive
Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease "Super Exacerbators".
Pulmonary Disease, Chronic Obstructive
PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase-1 by a mechanism dependent on MAP kinase phosphatase-1.
Pulmonary Disease, Chronic Obstructive
PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease.
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.
Pulmonary Disease, Chronic Obstructive
Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
Pulmonary Disease, Chronic Obstructive
Pharmacology of a novel, orally active PDE4 inhibitor.
Pulmonary Disease, Chronic Obstructive
Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors for the treatment of COPD.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase-4 inhibition in COPD.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Piclamilast inhibits the pro-apoptotic and anti-proliferative responses of A549 cells exposed to H(2)O(2) via mechanisms involving AP-1 activation.
Pulmonary Disease, Chronic Obstructive
Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases.
Pulmonary Disease, Chronic Obstructive
Prenylated Coumarins: Natural Phosphodiesterase-4 Inhibitors from Toddalia asiatica.
Pulmonary Disease, Chronic Obstructive
Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
Pulmonary Disease, Chronic Obstructive
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.
Pulmonary Disease, Chronic Obstructive
Production and characterization of pharmacologically active recombinant human phosphodiesterase 4B in Dictyostelium discoideum.
Pulmonary Disease, Chronic Obstructive
Prospects for new drugs for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.
Pulmonary Disease, Chronic Obstructive
Psiguajadials A-K: Unusual Psidium Meroterpenoids as Phosphodiesterase-4 Inhibitors from the Leaves of Psidium guajava.
Pulmonary Disease, Chronic Obstructive
Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.
Pulmonary Disease, Chronic Obstructive
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Pulmonary Disease, Chronic Obstructive
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Pulmonary Disease, Chronic Obstructive
Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast - a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Pulmonary Disease, Chronic Obstructive
Roflumilast Ameliorates Isoflurane-Induced Inflammation in Astrocytes via the CREB/BDNF Signaling Pathway.
Pulmonary Disease, Chronic Obstructive
Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Pulmonary Disease, Chronic Obstructive
Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.
Pulmonary Disease, Chronic Obstructive
Roflumilast for asthma: Efficacy findings in mechanism of action studies.
Pulmonary Disease, Chronic Obstructive
Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.
Pulmonary Disease, Chronic Obstructive
Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies.
Pulmonary Disease, Chronic Obstructive
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
Pulmonary Disease, Chronic Obstructive
Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Pulmonary Disease, Chronic Obstructive
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Pulmonary Disease, Chronic Obstructive
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Pulmonary Disease, Chronic Obstructive
Roflumilast Increases Bacterial Load and Dissemination in a Model of Pseudomononas Aeruginosa Airway Infection.
Pulmonary Disease, Chronic Obstructive
Roflumilast increases Clara cell secretory protein in cigarette smoke-exposed mice.
Pulmonary Disease, Chronic Obstructive
Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Pulmonary Disease, Chronic Obstructive
Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-? and Chemokine Production by Human Lung Parenchyma.
Pulmonary Disease, Chronic Obstructive
Roflumilast N-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells.
Pulmonary Disease, Chronic Obstructive
Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast Reduced the IL-18-Induced Inflammatory Response in Fibroblast-Like Synoviocytes (FLS).
Pulmonary Disease, Chronic Obstructive
Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.
Pulmonary Disease, Chronic Obstructive
Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model.
Pulmonary Disease, Chronic Obstructive
Roflumilast with long-acting {beta}2 agonists for COPD: influence of exacerbation history.
Pulmonary Disease, Chronic Obstructive
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.
Pulmonary Disease, Chronic Obstructive
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Pulmonary Disease, Chronic Obstructive
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Pulmonary Disease, Chronic Obstructive
Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
Pulmonary Disease, Chronic Obstructive
Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Pulmonary Disease, Chronic Obstructive
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast: A Review in COPD.
Pulmonary Disease, Chronic Obstructive
Roflumilast: a review of its use in the treatment of COPD.
Pulmonary Disease, Chronic Obstructive
Roflumilast: clinical benefit in patients suffering from COPD.
Pulmonary Disease, Chronic Obstructive
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Pulmonary Disease, Chronic Obstructive
Roflumilast: in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast: systemic therapy for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
Pulmonary Disease, Chronic Obstructive
Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.
Pulmonary Disease, Chronic Obstructive
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.
Pulmonary Disease, Chronic Obstructive
Selaginpulvilins A-D, new phosphodiesterase-4 inhibitors with an unprecedented skeleton from Selaginella pulvinata.
Pulmonary Disease, Chronic Obstructive
Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences.
Pulmonary Disease, Chronic Obstructive
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
Pulmonary Disease, Chronic Obstructive
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
Pulmonary Disease, Chronic Obstructive
Structure Based Design of Selective Phosphodiesterase 4B Inhibitors Based on Ginger Phenolic Compounds.
Pulmonary Disease, Chronic Obstructive
Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Pulmonary Disease, Chronic Obstructive
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Pulmonary Disease, Chronic Obstructive
Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Pulmonary Disease, Chronic Obstructive
Targeting lung inflammation: novel therapies for the treatment of COPD.
Pulmonary Disease, Chronic Obstructive
Tetomilast.
Pulmonary Disease, Chronic Obstructive
Tetomilast: new promise for phosphodiesterase-4 inhibitors?
Pulmonary Disease, Chronic Obstructive
The airway pathophysiology of COPD: implications for treatment.
Pulmonary Disease, Chronic Obstructive
The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting ?2-adrenoceptor agonist.
Pulmonary Disease, Chronic Obstructive
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
Pulmonary Disease, Chronic Obstructive
The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Pulmonary Disease, Chronic Obstructive
The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
Pulmonary Disease, Chronic Obstructive
The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.
Pulmonary Disease, Chronic Obstructive
The pharmacological approach to the elderly COPD patient.
Pulmonary Disease, Chronic Obstructive
The phosphodiesterase 4 inhibitor rolipram protects against cigarette smoke extract-induced apoptosis in human lung fibroblasts.
Pulmonary Disease, Chronic Obstructive
The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
Pulmonary Disease, Chronic Obstructive
The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
Pulmonary Disease, Chronic Obstructive
The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Pulmonary Disease, Chronic Obstructive
The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
Pulmonary Disease, Chronic Obstructive
The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys.
Pulmonary Disease, Chronic Obstructive
The use of roflumilast in COPD: a primary care perspective.
Pulmonary Disease, Chronic Obstructive
Therapeutic options for chronic obstructive pulmonary disease: present and future.
Pulmonary Disease, Chronic Obstructive
Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
Pulmonary Disease, Chronic Obstructive
Treatments for COPD.
Pulmonary Disease, Chronic Obstructive
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Pulmonary Disease, Chronic Obstructive
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD.
Pulmonary Disease, Chronic Obstructive
Vulnerable COPD patients with comorbidities: the role of roflumilast.
Pulmonary Disease, Chronic Obstructive
Warfarin pharmacodynamics unaffected by cilomilast.
Pulmonary Disease, Chronic Obstructive
[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].
Pulmonary Disease, Chronic Obstructive
[Acute exacerbation in COPD and asthma].
Pulmonary Disease, Chronic Obstructive
[Clinical profile of roflumilast].
Pulmonary Disease, Chronic Obstructive
[New treatments for chronic obstructive pulmonary disease]
Pulmonary Disease, Chronic Obstructive
[Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Pulmonary Disease, Chronic Obstructive
[Pharmacological profile of roflumilast].
Pulmonary Disease, Chronic Obstructive
[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Pulmonary Disease, Chronic Obstructive
[Prevention of acute exacerbation of chronic obstructive pulmonary disease].
Pulmonary Disease, Chronic Obstructive
[Selective phosphodiesterase 4 inhibition. Controlling inflammation--also in patients with COPD]
Pulmonary Disease, Chronic Obstructive
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD]
Pulmonary Disease, Chronic Obstructive
{blacktriangledown}Roflumilast for severe COPD?
Pulmonary Eosinophilia
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats.
Pulmonary Fibrosis
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
Pulmonary Fibrosis
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
Pyelonephritis
Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats.
Reperfusion Injury
Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury.
Reperfusion Injury
The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion.
Reperfusion Injury
Transcription Factor Trps1 Promotes Tubular Cell Proliferation after Ischemia-Reperfusion Injury through cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4D and AKT.
Respiratory Distress Syndrome
Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis.
Respiratory Insufficiency
Inhibition of protein kinase A and GIRK channel reverses fentanyl-induced respiratory depression.
Respiratory Insufficiency
Reversal by phosphodiesterase-4 blockers of in vitro apnea in the isolated brainstem-spinal cord preparation from newborn rats.
Rhinitis, Allergic
Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.
Rhinitis, Allergic
Inhibition of phosphodiesterase 4 in allergic rhinitis.
Rhinitis, Allergic
New therapies for allergic rhinitis.
Rhinitis, Allergic
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
Rubinstein-Taybi Syndrome
A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4.
Sarcoma
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Sarcoma
Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture.
Scleroderma, Systemic
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Sepsis
Circ_0091702 relieves lipopolysaccharide (LPS)-induced cell injury by regulating the miR-182/PDE7A axis in sepsis.
Sepsis
Cyclic adenosine monophosphate-phosphodiesterase inhibitors reduce skeletal muscle protein catabolism in septic rats.
Sepsis
Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation.
Sepsis
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Sepsis
Roflumilast as a Potential Therapeutic Agent for Cecal Ligation and Puncture-Induced Septic Lung Injury.
Sepsis
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
Sepsis
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
Shock, Septic
Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.
Skin Diseases
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
Skin Diseases
DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity.
Skin Diseases
Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
Skin Diseases
Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
Sleep Deprivation
Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.
Sleep Deprivation
Rolipram rescues memory consolidation deficits caused by sleep deprivation: Implication of the cAMP/PKA and cAMP/Epac pathways.
Sleep Deprivation
Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1.
Sleep Deprivation
Sleep deprivation impairs cAMP signalling in the hippocampus.
Spasm
Coronary vasodilatory, spasmolytic and cAMP-phosphodiesterase inhibitory properties of dihydropyranocoumarins and dihydrofuranocoumarins.
Spermatic Cord Torsion
Beneficial effects of rolipram, a phosphodiesterase 4 specific inhibitor, on testicular torsion-detorsion injury in rats.
Spinal Cord Injuries
A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes and tissue damage after spinal cord injury.
Spinal Cord Injuries
Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.
Spinal Cord Injuries
Meglumine cyclic adenylate improves neurological function following acute spinal cord injury in rats.
Spinal Cord Injuries
Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury.
Spinal Cord Injuries
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.
Spondylitis, Ankylosing
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.
Spondylitis, Ankylosing
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Spondylitis, Ankylosing
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Starvation
DdPDE4, a novel cAMP-specific phosphodiesterase at the surface of dictyostelium cells.
Starvation
Developmental regulation of the cyclic-nucleotide-phosphodiesterase mRNA of Dictyostelium discoideum. Analysis by cell-free translation and immunoprecipitation.
Stroke
ALOX5AP gene and the PDE4D gene in a central European population of stroke patients.
Stroke
Association between PDE4D gene and ischemic stroke: recent advancements.
Stroke
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Stroke
Association of SNP41, SNP56 and a novel SNP in PDE4D gene with stroke and its subtypes.
Stroke
Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort.
Stroke
Associations between SNP83 of phosphodiesterase 4D gene and carotid atherosclerosis in a southern Chinese Han population: a case-control study.
Stroke
Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort.
Stroke
Genes contributing to risk for common forms of stroke.
Stroke
Genetics of ischemic stroke: An Indian scenario.
Stroke
Genome-wide linkage scan of common stroke in families from northern Sweden.
Stroke
Identification of genetic contribution to ischemic stroke by screening of single nucleotide polymorphisms in stroke patients by using a case control study design (Study protocol).
Stroke
In silico pharmacology suggests ginger extracts may reduce stroke risks.
Stroke
Meta-Analysis of Homogeneous Subgroups Reveals Association between PDE4D Gene Variants and Ischemic Stroke.
Stroke
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Stroke
PDE4 Regulates Tissue Plasminogen Activator Expression of Human Brain Microvascular Endothelial Cells.
Stroke
Phosphodiesterase 4D (PDE4D) gene variants and the risk of ischemic stroke in a South Indian population.
Stroke
Phosphodiesterase 4D gene polymorphism is associated with ischaemic and haemorrhagic stroke.
Stroke
Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
Stroke
Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study.
Stroke
Phosphodiesterase 4D Single Nucleotide Polymorphism 83 and Cognitive Dysfunction in Carotid Endarterectomy Patients.
Stroke
Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
Stroke
Stroke genetics--focus on PDE4D gene.
Stroke
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke.
Stroke
The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target.
Stroke
[Association of cerebral stroke with a phosphodiesterase 4D (PDE4D) gene polymorphism in the Moscow population].
Stroke
[Phosphodiesterase 4D (PDE4D) gene polymorphism in patients with acute stroke from Moscow]
Stupor
Role of phosphodiesterase-4 on ethanol elicited locomotion and narcosis.
Subarachnoid Hemorrhage
Phosphodiesterase-4 inhibition confers a neuroprotective efficacy against early brain injury following experimental subarachnoid hemorrhage in rats by attenuating neuronal apoptosis through the SIRT1/Akt pathway.
Tachycardia
Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors.
Tardive Dyskinesia
Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
Thrombosis
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Thrombosis
Independent ischemic stroke risk factors in older Americans: a systematic review.
Thrombosis
The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
Thyroid Neoplasms
Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.
Trypanosomiasis, African
Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors.
Trypanosomiasis, African
Discovery of Diaryl Ether Substituted Tetrahydrophthalazinones as TbrPDEB1 Inhibitors Following Structure-Based Virtual Screening.
Trypanosomiasis, African
Discovery of Novel Trypanosoma brucei Phosphodiesterase B1 Inhibitors by Virtual Screening against the Unliganded TbrPDEB1 Crystal Structure.
Trypanosomiasis, African
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
Trypanosomiasis, African
Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.
Trypanosomiasis, African
Surface plasmon resonance biosensor assay for the analysis of small-molecule inhibitor binding to human and parasitic phosphodiesterases.
Tuberculosis
A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE).
Tuberculosis
Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.
Tuberculosis
Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.
Tuberculosis
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
Tuberculosis
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Tuberculosis
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
Tuberculosis, Meningeal
Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model.
Tuberculosis, Pulmonary
Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.
Tuberculosis, Pulmonary
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
unspecific monooxygenase deficiency
Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.
unspecific monooxygenase deficiency
The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.
Urinary Bladder, Overactive
Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.
Vascular Diseases
Association of phosphodiesterase 4D gene G0 haplotype and ischaemic stroke in a Greek population.
Vascular System Injuries
Altered gene expression in rat mesenteric tissue following in vivo exposure to a phosphodiesterase 4 inhibitor.
Vascular System Injuries
Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog.
Vascular System Injuries
Effects of modulating in vivo nitric oxide production on the incidence and severity of PDE4 inhibitor-induced vascular injury in sprague-dawley rats.
Vascular System Injuries
PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Vascular System Injuries
Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.
Vasculitis
Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor.
Ventricular Dysfunction, Left
Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting.
Virus Diseases
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Vitiligo
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.